Bio-Rad Laboratories, Inc. Share Price NYSE
Stocks
BIO.B
US0905721082
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
01:40:00 28/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 379.50 USD | +4.22% |
|
-.--% | +22.14% |
| 05/11 | RBC Raises Price Target on Bio-Rad Laboratories to $440 From $390, Keeps Outperform Rating | MT |
| 05/11 | Bio-Rad Laboratories Q3 Adjusted Earnings, Revenue Rise | MT |
| Market Cap | 1.03TCr 919.42Cr 840.27Cr 767.04Cr 1.45TCr 96TCr 1.49TCr 10TCr 4.04TCr 51TCr 3.85TCr 3.77TCr 1,62300Cr | P/E 2026 * |
45.9x | P/E 2027 * | 44.8x |
|---|---|---|---|---|---|
| Enterprise Value | 950.2Cr 852.24Cr 778.87Cr 710.99Cr 1.34TCr 89TCr 1.38TCr 9.39TCr 3.74TCr 48TCr 3.57TCr 3.49TCr 1,50500Cr | EV / Sales 2026 * |
3.7x | EV / Sales 2027 * | 3.55x |
| Free-Float |
60.67% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| BIO.B | Delayed | |
Deutsche Boerse AG
| BUW | Delayed |
Last Transcript: Bio-Rad Laboratories, Inc.
| 1 day | +4.22% | ||
| 1 month | +3.95% | ||
| 3 months | +12.61% | ||
| 6 months | +45.25% | ||
| Current year | +22.14% |
| 1 month | 364.15 |  | 379.5 |
| Current year | 244.54 | | 379.5 |
| 1 year | 244.54 | | 379.5 |
| 3 years | 0 | | 379.5 |
| 5 years | 0 | | 769.89 |
| 10 years | 0 | | 818.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 01/01/2003 |
| President | 61 | 09/09/2024 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 15/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 01/01/2012 |
Jeffrey Edwards
BRD | Director/Board Member | 73 | 25/04/2017 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 25/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.22% | -.--% | - | - | 1.03TCr | |
| -3.23% | +3.51% | -13.00% | +15.96% | 19TCr | |
| -2.90% | +5.45% | +10.41% | +40.45% | 12TCr | |
| -2.75% | +11.65% | -8.47% | +18.50% | 12TCr | |
| +0.96% | +5.15% | -37.16% | +12.09% | 9.93TCr | |
| -1.80% | +0.82% | -7.52% | +70.12% | 6.37TCr | |
| -0.78% | +7.07% | +19.14% | -17.27% | 5.77TCr | |
| +0.79% | +22.65% | -4.57% | +60.02% | 5.33TCr | |
| -6.98% | -14.56% | -11.97% | +46.23% | 4.7TCr | |
| -2.36% | +3.72% | +3.86% | -7.99% | 3.62TCr | |
| Average | -1.48% | +5.27% | -5.48% | +26.46% | 8.85TCr | |
| Weighted average by Cap. | -2.12% | +5.71% | -7.49% | +25.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 256.67Cr 230.21Cr 210.39Cr 192.06Cr 361.85Cr 24TCr 373.26Cr 2.54TCr 1.01TCr 13TCr 963.43Cr 942.77Cr 41TCr | 261.46Cr 234.5Cr 214.31Cr 195.64Cr 368.59Cr 25TCr 380.21Cr 2.58TCr 1.03TCr 13TCr 981.38Cr 960.33Cr 41TCr |
| Net income | 22Cr 20Cr 18Cr 17Cr 32Cr 2.11TCr 33Cr 222.15Cr 89Cr 1.13TCr 84Cr 83Cr 3.56TCr | 23Cr 21Cr 19Cr 17Cr 32Cr 2.16TCr 33Cr 226.96Cr 91Cr 1.15TCr 86Cr 84Cr 3.64TCr |
| Net Debt | -75Cr -67Cr -61Cr -56Cr -105.59Cr -7.04TCr -108.92Cr -740.04Cr -295.09Cr -3.76TCr -281.14Cr -275.11Cr -12TCr | -97Cr -87Cr -79Cr -72Cr -136.1Cr -9.08TCr -140.39Cr -953.85Cr -380.35Cr -4.84TCr -362.37Cr -354.6Cr -15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | $0.000000 | - | 10 |
| 05/26/05 | $0.000000 | - | 1 |
| 04/26/04 | $0.000000 | - | 28 |
| 03/26/03 | $0.000000 | - | 12 |
| 02/26/02 | $0.000000 | - | 13 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
- BIO.B Stock
Select your edition
All financial news and data tailored to specific country editions
